Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Reveals Six Potential Late Stage (Phase III) Candidates, and Ten Late Stage (Phase II, I and Preclinical Trials) Candidates: Transparency Market Research


News provided by

Transparency Market Research

08 Sep, 2014, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

ALBANY, New York, September 8, 2014 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" six phase III drugs would generate total revenue of USD 3.8 billion by 2020.

Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html

Hospital acquired infections also called as healthcare associated infections or nosocomial infections have raised serious concerns due to multidrug resistance shown by microorganisms. Multidrug resistant organisms are immune to the conventional antibiotics, hence very difficult to treat. Pneumonia accounts for over 22% of all the hospital acquired infections. Since hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator, it is also called as ventilator associated pneumonia. The infection is common in immunocompromised patients, post surgical infections, enteral feeding, and in elderly and infant patients. Various gram positive as well as gram negative bacteria are known to cause hospital acquired pneumonia. Major causative agents include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) is found to be a major causative agent of nosocomial pneumonia in new borne.  

Currently there are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage. Phase III candidates include Tedizolid phosphate and Ceftolozane/tazobactam by Cubist Pharmaceuticals, Ceftazidime/avibactam by AstraZeneca PLC, Amikacin inhale by Bayer Healthcare, Plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline. Majority of these drugs are expected to be launched by 2017. Analysis reveals that majority of the candidates in late stage are biological drugs. This indicates a paradigm shift from traditional antibiotic therapy to more sophisticated biological drug therapy. Aridis Pharmaceuticals hold a strong monoclonal antibody pipeline with four candidates for treatment of hospital acquired pneumonia which was acquired from Kenta Biotech in 2013.  

Related & Recently Published Reports by Transparency Market Research 

  • Molecular Cytogenetics Market: http://www.transparencymarketresearch.com/molecular-diagnostics-market.html
  • Pharmacy Automation Systems Market: http://www.transparencymarketresearch.com/pharmacy-automation-systems.html
  • Peptide Therapeutics Market: http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Growing drug resistance has been a major concern in hospitals globally. According to a report published by Centers for Disease Control and Prevention (CDC) in 2013 which considers the U.S. population for study, 63% of Acinetobacter is considered multi drug resistant. Methicillin resistant Staphylococcus aureus (MRSA) is one of the most hazardous organisms causing ventilator-associated pneumonia. CDC estimates that over 80,400 MRSA infections occurred in 2011, of which more than 11,000 patients died. Furthermore, World Health Organization (WHO) suggests that prevalence of nosocomial infections is higher in low and middle income countries. This suggests that the conditions are more alarming in these regions. In addition, rate of hospital acquired infections have been declining since recent past according to statistics published by Office National Statistics, U.K.

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

Get Sample Copy of Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

Hospital Acquired Pneumonia Drug Pipeline is as follows:

Global Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III) 

  • Tedizolid phosphate    
  • Ceftolozane/tazobactam
  • Ceftazidime/avibactam
  • Amikacin inhale
  • Plazomicin
  • Synflorix

Global Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II, Phase I and Preclinical Trials) 

  • AR-101 or KBPA101
  • GSK 2189242A
  • BAL30072
  • MEDI4893
  • AR 301 or KBSA301
  • ME1100
  • V114
  • AR-104 or KBPA104
  • AR-201 or KBRV201
  • AR-401 or KBAB401

Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact 

Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Company Blog: http://www.tmrblog.com/

Company Blog: http://www.europlat.org/

Browse All PR: http://www.transparencymarketresearch.com/press-releases.htm

Browse All Articles: http://www.transparencymarketresearch.com/articles.htm

Browse Press Release "six phase III drugs would generate total revenue of USD 3.8 billion by 2020" at @ http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Publishing & Information Services

Publishing & Information Services

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.